knowledge -WSS

knowledge

author：entertainment 2025-10-02 10:48:21 - browse：3

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Cholera vaccine supply gets boost as demand surges globally

knowledge

WSS

MultiPlan and major insurers sued for alleged medical price

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Medical bills so high, Medicare adding extra digits to claim forms

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Wearables generate powerful data but its not useful to doctors, yet

H5N1 bird flu found in pasteurized milk: what we know

focus

knowledge

leisure time

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

When prostate cancer spreads, where it goes matters

Cancer drug shortages should be causing more outrage

Criminal prosecution for violating HIPAA: an emerging threat

ChatGPT in medicine: STAT answers readers' burning questions

Bird flu in milk supply is likely coming from asymptomatic cows

23andMe had bad news about my health. I wish a person had delivered it

Criminal prosecution for violating HIPAA: an emerging threat

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

focus

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Wearables generate powerful data but its not useful to doctors, yet

Criminal prosecution for violating HIPAA: an emerging threat

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

H5N1 bird flu virus started spreading in cows in Texas in December

Cytokinetics CEO stresses company can launch heart drug on its own

entertainment

knowledge

knowledge

knowledge